Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients.
Angiotensin II type 1 receptor blocker
Angiotensin converting enzyme inhibitor
Calcium channel blocker
Diabetes mellitus
Journal
Journal of diabetes and metabolic disorders
ISSN: 2251-6581
Titre abrégé: J Diabetes Metab Disord
Pays: Switzerland
ID NLM: 101590741
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
27
11
2019
accepted:
20
03
2020
entrez:
19
6
2020
pubmed:
19
6
2020
medline:
19
6
2020
Statut:
epublish
Résumé
Rare comparative studies investigated the relationship between combination therapy of antihypertensive drugs and the incidence of new-onset diabetes mellitus (NODM). The aim of this study was to evaluate which combination therapy, calcium channel blocker (CCB) with angiotensin converting enzyme inhibitor (ACEI) or CCB with angiotensin II type 1 receptor blocker (ARB), is best in reducing/preventing the development of NODM during 4-year follow-up periods in non-diabetic hypertensive Korean patients. Finally, a total of 1221 consecutive hypertensive patients without a history of diabetes mellitus who had been prescribed CCB were retrospectively enrolled and divided into the two groups, an ACEI group (combination CCB with ACEI, After propensity-score matched (PSM) analysis, two propensity-matched groups (243 pairs, CCB with ACE or CCB with ARB combination strategies are equally acceptable in hypertensive Korean patients regarding the occurrence of NODM.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Rare comparative studies investigated the relationship between combination therapy of antihypertensive drugs and the incidence of new-onset diabetes mellitus (NODM). The aim of this study was to evaluate which combination therapy, calcium channel blocker (CCB) with angiotensin converting enzyme inhibitor (ACEI) or CCB with angiotensin II type 1 receptor blocker (ARB), is best in reducing/preventing the development of NODM during 4-year follow-up periods in non-diabetic hypertensive Korean patients.
MATERIALS AND METHODS
METHODS
Finally, a total of 1221 consecutive hypertensive patients without a history of diabetes mellitus who had been prescribed CCB were retrospectively enrolled and divided into the two groups, an ACEI group (combination CCB with ACEI,
RESULTS
RESULTS
After propensity-score matched (PSM) analysis, two propensity-matched groups (243 pairs,
CONCLUSION
CONCLUSIONS
CCB with ACE or CCB with ARB combination strategies are equally acceptable in hypertensive Korean patients regarding the occurrence of NODM.
Identifiants
pubmed: 32550191
doi: 10.1007/s40200-020-00521-4
pii: 521
pmc: PMC7270230
doi:
Types de publication
Journal Article
Langues
eng
Pagination
405-413Informations de copyright
© Springer Nature Switzerland AG 2020.
Déclaration de conflit d'intérêts
Conflict of interestThe authors state that there is no conflict of interests in the present research study.
Références
Am J Cardiol. 2007 Apr 1;99(7):1006-12
pubmed: 17398202
Hypertens Res. 2011 Dec;34(12):1295-301
pubmed: 21833000
Hypertens Res. 2006 Aug;29 Suppl:S1-105
pubmed: 17366911
J Hypertens. 2005 Mar;23(3):463-73
pubmed: 15716683
JAMA. 2002 Dec 18;288(23):2981-97
pubmed: 12479763
Diabetes Care. 1991 Mar;14(3):203-9
pubmed: 1828417
Drug Res (Stuttg). 2014 May;64(5):276-80
pubmed: 24132701
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Am Heart J. 1988 Mar;115(3):640-56
pubmed: 3278578
Int J Cardiol. 2016 Aug 15;217:128-34
pubmed: 27179902
JAMA. 2000 Apr 19;283(15):1967-75
pubmed: 10789664
Trends Pharmacol Sci. 2011 Dec;32(12):734-9
pubmed: 21880378
GMS Health Technol Assess. 2010 Mar 16;6:Doc03
pubmed: 21289876
Diabetes Res Clin Pract. 2000 Dec;50(3):231-9
pubmed: 11106838
Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):979-87
pubmed: 17605137
N Engl J Med. 2009 Oct 1;361(14):1339-48
pubmed: 19797280
Diabetes Care. 2004 Jan;27(1):247-55
pubmed: 14693997
Eur Heart J. 2013 Jul;34(28):2159-219
pubmed: 23771844
Lancet. 1999 Feb 20;353(9153):611-6
pubmed: 10030325
Lancet. 2007 Jan 20;369(9557):201-7
pubmed: 17240286
Lancet. 1998 Jun 13;351(9118):1755-62
pubmed: 9635947
Obstet Gynecol Sci. 2020 Jan;63(1):19-26
pubmed: 31970124
Am J Cardiol. 2011 Jun 15;107(12):1705-9
pubmed: 21507365
Diabetes Care. 2013 Jan;36 Suppl 1:S67-74
pubmed: 23264425
Epidemiol Health. 2019;41:e2019040
pubmed: 31679329
Drugs. 2004;64(22):2537-65
pubmed: 15516153
Hypertension. 2003 Dec;42(6):1206-52
pubmed: 14656957
Diabetes Obes Metab. 2012 Jul;14(7):586-95
pubmed: 22226145
Am J Physiol. 1999 Jul;277(1):R332-6
pubmed: 10409290
Curr Med Res Opin. 2007 Jun;23(6):1239-44
pubmed: 17559720
J Cell Mol Med. 2017 Sep;21(9):1742-1750
pubmed: 28230330
J Hypertens. 2003 Jun;21(6):1011-53
pubmed: 12777938
J Hypertens. 2007 May;25(5):951-8
pubmed: 17414657
Curr Med Res Opin. 2011 Apr;27(4):799-807
pubmed: 21306286
JAMA. 2003 Dec 3;290(21):2805-16
pubmed: 14657064
Nihon Rinsho. 2002 Oct;60(10):1945-8
pubmed: 12397689
Cardiol J. 2010;17(5):448-56
pubmed: 20865674